A detailed history of Glenmede Trust CO Na transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Glenmede Trust CO Na holds 132,818 shares of VRTX stock, worth $68.6 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
132,818
Previous 135,081 1.68%
Holding current value
$68.6 Million
Previous $56.5 Million 10.25%
% of portfolio
0.32%
Previous 0.28%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $888,929 - $1.1 Million
-2,263 Reduced 1.68%
132,818 $62.3 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $15.9 Million - $17.4 Million
-39,015 Reduced 22.41%
135,081 $56.5 Million
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $6.96 Million - $8.34 Million
-20,297 Reduced 10.44%
174,096 $70.8 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $1.47 Million - $1.58 Million
-4,348 Reduced 2.19%
194,393 $67.6 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $33,328 - $37,302
-106 Reduced 0.05%
198,741 $69.9 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $2.31 Million - $2.63 Million
8,144 Added 4.27%
198,847 $62.7 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $8.85 Million - $9.96 Million
30,980 Added 19.4%
190,703 $55.1 Million
Q3 2022

Nov 16, 2022

BUY
$273.83 - $305.53 $589,008 - $657,195
2,151 Added 1.37%
159,723 $46.2 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $799,568 - $995,547
-3,403 Reduced 2.11%
157,572 $44.4 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $32.6 Million - $38.4 Million
147,028 Added 1054.19%
160,975 $42 Million
Q4 2021

Feb 15, 2022

SELL
$177.01 - $223.45 $238,078 - $300,540
-1,345 Reduced 8.8%
13,947 $3.06 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $452,205 - $506,054
2,493 Added 19.48%
15,292 $2.77 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $1.18 Million - $1.39 Million
6,295 Added 96.79%
12,799 $2.58 Million
Q1 2021

May 18, 2021

SELL
$207.02 - $241.31 $12.2 Million - $14.3 Million
-59,113 Reduced 90.09%
6,504 $1.4 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $12.8 Million - $17.1 Million
61,958 Added 1693.3%
65,617 $15.5 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $140,607 - $166,705
550 Added 17.69%
3,659 $994,000
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $133,935 - $175,705
594 Added 23.62%
3,109 $901,000
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $15,670 - $21,047
-94 Reduced 3.6%
2,515 $550,000
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $48,539 - $54,630
292 Added 12.6%
2,609 $441,000
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $67,325 - $77,861
409 Added 21.44%
2,317 $424,000
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $45,189 - $53,737
-276 Reduced 12.64%
1,908 $350,000
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $67,448 - $85,341
444 Added 25.52%
2,184 $361,000
Q3 2018

Nov 15, 2018

BUY
$167.73 - $192.74 $7,715 - $8,866
46 Added 2.72%
1,740 $334,000
Q2 2018

Aug 15, 2018

SELL
$145.72 - $169.96 $12,677 - $14,786
-87 Reduced 4.88%
1,694 $288,000
Q4 2017

Feb 15, 2018

BUY
$137.28 - $155.55 $3,706 - $4,199
27 Added 1.54%
1,781 $266,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $259,820 - $284,568
1,754
1,754 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Glenmede Trust CO Na Portfolio

Follow Glenmede Trust CO Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.